| Identification | Back Directory | [Name]
FM-381 | [CAS]
2226521-65-7 | [Synonyms]
FM-381
CS-2854
FM-381; FM 381; FM381
2-Propenamide, 2-cyano-3-[5-(1-cyclohexyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-2-furanyl]-N,N-dimethyl-
(E/Z)-2-Cyano-3-(5-(1-cyclohexyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)furan-2-yl)-N,N-dimethylacrylamide | [Molecular Formula]
C24H24N6O2 | [MDL Number]
MFCD31630713 | [MOL File]
2226521-65-7.mol | [Molecular Weight]
428.49 |
| Hazard Information | Back Directory | [Biological Activity]
FM-381 is a highly potent and JAK3-selective janus kinase (JAK) inhibitor (IC50 = 127 pM/JAK352 nM/JAK1346 nM/JAK2459 nM/TYK2 by radiometric assay; [ATP] = 10 μM) th at targets JAK3 gatekeeper (GK) Cys909 for a reversible covalent interactionexhibiting much reduced or little potency against a panel of 409 other kinases. FM-381 is >3-fold more potent than the JAK1/3 inhibitor Tofacitinib (IC50 = 292 pM/JAK3496 pM/JAK12.2 nM/JAK28.9 nM/TYK2 by radiometric assay; [ATP] = 10 μM) in blocking JAK1/JAK3-mediated STAT5 phosphorylation in human CD4+ T-cells upon IL-2 stimulation (ECmax ∼100 nM with FM-381)while being ineffective (up to 1 μM) against JAK3-independent STAT1/3 phosphorylation following IL-6 or TNFα stimulation. For characterization details of FM-381please visit the FM-381 probe summary on the Structural Genomics Consortium (SGC) website.
FM-479 is the negative control |
|
|